Da Jian Zhong Tang (Major Construct the Middle Decoction)

Actions

Indications

Western Uses:

• What conditions is Da Jian Zhong Tang used for in modern practice?

  Da Jian Zhong Tang warms deep interior cold from yang deficiency (severe cold abdominal pain, spasm, and vomiting), so it is referenced for cold-type abdominal and digestive conditions: chronic gastritis, chronic pancreatitis, chronic cholecystitis, urinary stones (calculi), uncomplicated intestinal obstruction, cramping abdominal pain, biliary ascariasis, duodenal ulcer, and vomiting.

  It is selected for the interior-cold / yang-deficiency pattern, not for a diagnosis. Severe or sudden abdominal pain requires medical assessment — obstruction, pancreatitis and biliary disease can be emergencies — and an ulcer needs medical treatment (including H. pylori testing). Traditional-use correlates only, not a treatment claim.

  Source: Sacred Lotus sources & references (pattern) + Bensky & Barolet, Formulas & Strategies; biomedical correlates as reference only. Not medical advice.

Originally Appeared In:

• Essentials from the Golden Cabinet (Jin Gui Yao Lue)

Notes:

• How does Da Jian Zhong Tang differ from Xiao Jian Zhong Tang and Li Zhong Wan?

  All three formulas warm and tonify the Middle Burner, but they sit at different points on a severity scale: Xiao Jian Zhong Tang (“Minor”) is a gentle Spleen/Stomach-harmonizing formula for mild, deficiency-type cramping; Li Zhong Wan (“Regulate the Middle”) is a moderate, balanced Middle-Burner Yang tonic for chronic cold-deficiency with diarrhea; Da Jian Zhong Tang (“Major”) is reserved for the most severe, acute cold presentation with visible peristalsis or masses. The shared “Jian Zhong” (“construct the Middle”) and “Zhong” naming across two of these formulas signals the family relationship, but the clinical pictures are quite distinct.

  • Xiao Jian Zhong Tang (Minor Construct the Middle Decoction): built on Gui Zhi Tang with a doubled dose of Bai Shao and a large amount of Yi Tang, for mild-to-moderate Spleen/Stomach deficiency with cold — a dull, intermittent abdominal ache that is relieved (not worsened) by warmth and pressure, often with some concurrent exterior weakness. It has no Chuan Jiao or Gan Jiang and is far milder than Da Jian Zhong Tang.
  • Li Zhong Wan (Regulate the Middle Pill, also Ren Shen Tang): Ren Shen, Bai Zhu, Gan Jiang, and Zhi Gan Cao, for a steadier, more chronic Spleen/Stomach Yang deficiency with cold — poor appetite, loose stools, and a mild, diffuse cold sensation, without the severe pain or visible peristalsis that define Da Jian Zhong Tang’s presentation.
  • Da Jian Zhong Tang (this formula): reserved for the most acute, severe end of this spectrum — sharp pain worsened by pressure, visible or palpable peristaltic movement, and near-total inability to eat, treated with the much stronger, more acrid Shu Jiao and higher-dose Gan Jiang rather than the gentler herbs of the other two formulas.

  Classical source: Da Jian Zhong Tang is recorded in the Jin Gui Yao Lue (Essential Prescriptions of the Golden Cabinet), compiled by the Han-dynasty physician Zhang Zhongjing — one of the foundational classical formula texts still taught today. In modern Japanese Kampo medicine the same formula is known as Daikenchuto (also written Dai-kenchu-to, marketed as TJ-100/TU-100) and is one of the most extensively clinically studied Kampo formulas, particularly for postoperative bowel recovery (see research).

  Source: Bensky & Barolet, Formulas & Strategies; Chen & Chen, Chinese Herbal Formulas and Applications (formula comparisons, classical source, and Kampo naming). Traditional-use framing.

Clinical Studies & Research:

• Is there modern research on Da Jian Zhong Tang (Daikenchuto)?

  Yes — as Daikenchuto, this formula is among the most clinically studied Kampo medicines, with the strongest evidence in postoperative bowel recovery after gastrointestinal surgery. A 2017 systematic review and meta-analysis of seven studies (1,134 patients undergoing gastrointestinal cancer surgery) found that perioperative Daikenchuto significantly reduced postoperative ileus (11.4% versus 15.9% in controls, risk ratio 0.58) (PMID 29061775).

  • Postoperative ileus after GI cancer surgery (systematic review/meta-analysis, 7 studies, 1,134 patients): perioperative Daikenchuto significantly reduced postoperative ileus incidence, risk ratio 0.58 (PMID 29061775).
  • Total gastrectomy for gastric cancer (multicenter randomized, double-blind, placebo-controlled Phase II trial, 245 patients): median time to first bowel movement was faster with Daikenchuto than placebo (94.7 vs 113.9 hours overall, reaching significance in patients with high treatment adherence: 93.8 vs 115.1 hours, p=0.014), supporting a role in early postoperative bowel-function recovery (PMID 26141466).
  • Functional constipation in women (randomized, placebo-controlled trial, 45 patients, TU-100): by contrast, this trial found no significant effect on gastrointestinal or colonic transit, rectal compliance, or anal sphincter pressures, and no improvement in stool frequency, consistency, or quality of life versus placebo — a negative result for this particular indication (PMID 23451764).

  Taken together, the clinical evidence base is strongest for perioperative bowel-function recovery after gastrointestinal surgery and notably does not support benefit for functional constipation in the one placebo-controlled trial identified; this is a mixed picture, not uniform support, and none of it establishes a treatment for the classical severe-cold abdominal-pain pattern this formula was originally designed for.

  Sources: PubMed 29061775 (Anticancer Research, 2017); PubMed 26141466 (Journal of the American College of Surgeons, 2015); PubMed 23451764 (Alimentary Pharmacology & Therapeutics, 2013). Research context, not a therapeutic claim.